Answers are grounded in this paper and cite their sources.
Solution-based study evaluates simvastatin's binding effects on complement receptor 3 in a murine model, suggesting different mechanisms of action.
Simvastatin is a primary cholesterol-lowering medication, but it has also been reported to possess anti-inflammatory properties. Notably, the CD18 integrins are targets for simvastatin antagonism of ligand binding, which may affect leukocyte adhesion and diapedesis. Lymphocyte-associated antigen (LFA)-1 is inhibited through an allosteric mechanism by binding the lactone form of simvastatin (simvastatin-lac) to a hydrophobic pocket in the major ligand binding domain, the alpha chain I domain. By contrast, crystallographic evidence showed that complement receptor 3 (CR3) is inhibited by simvastatin in its carboxylate form (simvastatin-carbox) chelated by an Mg 2+ ion in the α M I metal ion-dependent adhesion site (MIDAS). We now report that the affinity ( K D ) of simvastatin-carbox for the α M I is ~650 μM, which is significantly weaker than the 50 %-inhibitory concentration of simvastatin-lac at 50 μM. The simvastatin-carbox was incapable of inhibiting CR3 binding to iC3b, nor did it exert any neuroprotective or anti-inflammatory effects in the middle cerebral artery occlusion animal model of stroke, unlike what has been reported for simvastatin-lac. From available structural data on the CR3 ligand binding domain in complex with C3d, we suggest that simvastatin-lac makes a critical ternary complex with the ligand binding domain and its ligand before engaging, in its carboxylate form, the MIDAS. In this way, both the LFA-1 and CR3 are antagonized by simvastatin-lac but through fundamentally different mechanisms. • NOESY confirmed the interaction between the CR3 I domain Mg 2+ ion and simvastatin-carbox in solution. • The CR3 I domain binds simvastatin-carbox with a K D of ~650 μM. • While simvastatin-lac inhibited CR3 adhesion to complement, the carboxylate form is not an antagonist. • Unlike simvastatin-lac, simvastatin-carbox has no neuroprotective or anti-inflammatory effects in a murine stroke model.
No takes yet. Share an insight, caveat, or question.
Fog et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: